TransCode stockholders approve reverse stock split of RNAZ common stock at ratio between 1:10 and 1:40

Transcode Therapeutics, Inc.

Special meeting Jan 8, 2024: 12,472,113 shares voted of 25,097,596 entitled.
Reverse split approved: 7,081,896 for, 5,348,629 against, 41,588 abstentions.
Board has discretion to implement the split at a specific ratio and timing.
Adjournment proposal passed (7,426,024 for) but not needed after reverse split approval.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Transcode Therapeutics, Inc. shareholders approved Approval of an adjournment of the Special Meeting to the extent there are insufficient votes at the Special Meeting to approve the reverse stock split proposal at the 2024-01-08 meeting.

Proposal: reverse split
Outcome: passed
Meeting: 2024-01-08

Exact text from the filing

(ii) The Adjournment Proposal: Stockholders approved the Adjournment Proposal. The results of the voting included 7,426,024 votes for, 4,836,062 votes against and 210,027 votes abstained. There were no broker non-votes regarding this proposal.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Transcode Therapeutics, Inc. shareholders approved Amendment to Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company's outstanding shares of common stock by a ratio of any whole number between 1-for-10 and 1-for-40 at the 2024-01-08 meeting.

Proposal: reverse split
Outcome: passed
Meeting: 2024-01-08

Exact text from the filing

The number of votes cast for and against and the number of abstentions and broker non-votes with respect to each matter voted upon are set forth below: (i) The Reverse Stock Split Proposal: Stockholders approved the Reverse Stock Split Proposal. The results of the voting included 7,081,896 votes for, 5,348,629 votes against and 41,588 votes abstained. There were no broker non-votes regarding this proposal.

View on SEC.gov

224 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Transcode Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-002225

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.